Meyer, Colin J.

Bardoxolone Methyl and Kidney Function in CKD with Type 2 Diabetes

Pergola, P. E., Raskin, P., Toto, R. D., Meyer, C. J., Huff, J. W., Grossman, E. B., Krauth, M., Ruiz, S., Audhya, P., Christ-Schmidt, H., et al. (2011) · New England Journal of Medicine

Chronic Kidney Disease and DiabetesAcute Kidney Injury Research

Cited by 890

A phase I first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomas

Hong, D. S., Kurzrock, R., Supko, J. G., He, X., Naing, A., Wheler, J., Lawrence, D., Eder, J. P., Meyer, C. J., Ferguson, D. A., et al. (2012) · Clinical Cancer Research

Genomics, phytochemicals, and oxidative stressBioactive Compounds and Antitumor Agents

Cited by 236

Triterpenoid CDDO-methyl ester inhibits the Janus-activated kinase-1 (JAK1)-->signal transducer and activator of transcription-3 (STAT3) pathway by direct inhibition of JAK1 and STAT3

Ahmad, R., Raina, D., Meyer, C., & Kufe, D. (2008) · Cancer Research

Cytokine Signaling Pathways and InteractionsNatural product bioactivities and synthesis

Cited by 120

Dihydro-CDDO-Trifluoroethyl Amide (dh404), a Novel Nrf2 Activator, Suppresses Oxidative Stress in Cardiomyocytes

Ichikawa, T., Li, J., Meyer, C. J., Janicki, J. S., Hannink, M., & Cui, T. (2009) · PLoS ONE

Genomics, phytochemicals, and oxidative stressRedox biology and oxidative stress

Cited by 99